|
Activ8rlives’ Asthma+me
solution looking to expand
to UAE and Saudi Arabia
(St
Ives, Cambridgeshire,
UK) -
Aseptika
Ltd (Activ8rlives) are
attending Arab Health and
are looking to expand
efforts in establishing
collaborations with
clinicians and hospitals
specialising in childhood
asthma, seeking investment
and a manufacturing base in
the United Arab Emirates and
Saudi Arabia.
Research from the Global
Asthma Network, points to
approximately 14% of the UAE
population are impacted by
asthma, well above the
global average because of
the dusty conditions and
seasonal changes. From the
UAE and Saudi Arabia, we
have had significant
interest in the early
results from the Randomised
Controlled Trial of our
Asthma+me solution for
children aged 6-12 years
with moderate-to-severe
asthma. For further
information, come and visit
our Stand H2-G50 to discuss
the Asthma+me solution and
learn how it can be
translated into your
language with a local
educational syllabus.
Asthma+me was co-designed
with a Paediatrician at an
NHS Trust (UK) supporting
the transition from
treatment in specialist
paediatric clinics to
community care, with an
initial focus on meeting the
needs of children aged 6-12
years with
moderate-to-severe asthma.
It supports wireless medical
monitors, medication
diaries, trigger alerts for
pollution/pollen/weather,
symptoms tracking, care
plan, an extensive
educational syllabus and
weekly reports going
directly to their hospital
records.
The Asthma+me App is used
with the Activ8rlives
PUFFClickerTM smart tracker
for pressurised metered-dose
inhalers pMDIs, counting
doses, recording inhaler
shaken properly and timer
supporting improved inhaler
technique. Asthma+me
provides basic disease
monitoring via connected
devices, patient and parent/carer
education, medication
adherence, motivational
support through self-care to
reduce severity of asthma
attacks, reducing A&E and
hospital admissions.
Children are involved in
setting their goals and are
motivated by incentives from
parent/carer to promote
behaviour change, increasing
adherence to their Care
Plan, which is generated
automatically on their
Smartphone.
The Asthma+me App and
Activ8rlives PUFFClicker
Smart Inhaler Tracker are
both approved as Class 1
Medical Devices under MDD
and the Asthma+me App will
transition to MDR as a Class
IIa medical devices through
a UK Notified Body.
What is unique about it?
Current development and
integration of AI components
during the RCT will
significantly enhance the
solution allowing disease
status reporting to the
specialist clinic, less
clinician time and in-built
expertise for patients and
parents. The Asthma+me App
is the first remote
monitoring self-management
solution in paediatric
clinical trials, that allows
risk stratification on need,
a personalised-care
approach, thereby reducing
emergency admissions,
improving patient safety and
quality-of-life.
How does it benefit
clinicians and patients?
Lack of medication adherence
is a global problem, with
£300million worth of
medications/year wasted in
primary care, with 50% of
patients are not taking
their medication as
prescribed. Asthma is the
most common chronic medical
condition among UK
Children/Young People. The
cost associated with
treating all types of asthma
is significant. In the UK
10% of children with asthma
are clinically-defined as
moderate-to-severe or
difficult-to-treat asthma
and should be treated in
specialist paediatric
hospital clinics. There are
no current comparators to
Asthma+me worldwide.
What healthcare system
need does your product meet?
Reducing Outpatient
Appointments at tertiary
hospital clinics for
moderate-to-severe asthmatic
children 6-12 years, so that
more first appointments can
be provided to other
children. It also assists
with medication adherence,
education, improved
self-confidence in self-care
of childhood asthma,
reduction of admissions and
improved use of NHS
resources.
Health economics
Assuming the average cost
per family of each child
with moderate-to-severe
asthma treated as
Out-Patient is
£5,000-6,000pa in the UK.
The intervention would need
to provide 13.3% reduction
in costs to be cash-neutral
in Year 1. This does not
include the costs associated
with lost work-school days,
reduced CO2 emissions or
benefit of reducing waiting
times for first appointments
at paediatric clinics. As
part of the Asthma+me RCT a
health economics study will
be undertaken to look at the
financial and health impacts
of this innovative Asthma+me
care pathway.
Activ8rlives Asthma+me
solution generates huge
amounts of data, making it
challenging to review all
the patient data. Internal
development programmes have
demonstrated the use of Deep
Learning/Neural Networks
(Artificial Intelligence)
that can be used to
accurately forewarn of
decline in health by up to
7-days and providing
patients and parents/carers
with actionable insights
with enough time to start
emergency treatment with
antibiotics or steroids for
example.
Activ8rlives,
Activ8rlives.com, Asthma+me
and Active+me are trademarks
of Aseptika Ltd.
PRINT
THIS ARTICLE
|